Articles by Teresa B. Gibson, PhD

The authors provide a framework to capture additional benefits that may result from VBID programs, extending beyond utilization and outcomes to productivity, engagement, and talent.

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice
ByTeresa B. Gibson, PhD,Emily D. Ehrlich, MPH,Jennifer Graff, PharmD,Robert Dubois, MD,Amanda M. Farr, MPH,Michael E. Chernew, PhD,A. Mark Fendrick, MD The authors found no consistent pattern in the concordance between CER evidence and subsequent utilization patterns.

Value-Based Insurance Design: Perspectives, Extending the Evidence, and Implications for the Future
ByJohn J. Mahoney, MD, MPH,Karlene Lucas, MBA,Teresa B. Gibson, PhD,Emily D. Ehrlich, MPH,Justin Gatwood, MPH,Brian J. Moore, PhD,Kim A. Heithoff, ScD 
Impact of Cost-Sharing on Treatment Augmentation in Patients With Depression
ByTeresa B. Gibson, PhD,Yonghua Jing, PhD,Jill E. Bagalman, MSW,Zhun Cao, PhD,John A. Bates, PhD,Tony Hebden, PhD,Robert A. Forbes, PhD,Jalpa A. Doshi, PhD Higher patient cost-sharing is associated with a lower likelihood of treatment augmentation in patients with depression who are treated with antidepressants.

Cost Sharing, Adherence, and Health Outcomes in Patients With Diabetes
ByTeresa B. Gibson, PhD,Xue Song, PhD,Berhanu Alemayehu, DrPH,Sara S. Wang, PhD,Jessica L. Waddell, MPH,Jonathan R. Bouchard, MS, RPh,Felicia Forma, BSc Higher cost-sharing levels reduced adherence to antidiabetic medications in patients with type 2 diabetes.

Cost Burden of Treatment Resistance in Patients With Depression
ByTeresa B. Gibson, PhD,Yonghua Jing, PhD,Ginger Smith Carls, PhD,Edward Kim, MD, MBA,J. Erin Bagalman, MSW,Wayne N. Burton, MD,Quynh-Van Tran, PharmD,Andrei Pikalov, MD, PhD,Ron Z. Goetzel, PhD When a clinical staging algorithm for treatment-resistant depression was applied to administrative claims data, higher scores predicted higher future medical costs.

Traditional Medicare and the large-firm commercial sector have a positive correlation in hospital utilization, but a lack of correlation in spending.

Are There Unintended Consequences of Step-Therapy Programs?
ByEmily R. Cox, RPh, PhD,Brian J. Seiz, PharmD. Reply by Tami L. Mark, PhD, MBA,Teresa B. Gibson, PhD,Kimberly A. McGuigan, PhD 
Step therapy with antihypertensives may lead to medication cost savings but may have unintended effects on other medical care utilization and spending.

Impact of Statin Copayments on Adherence and Medical Care Utilization and Expenditures
ByTeresa B. Gibson, PhD,Tami L. Mark, PhD, MBA,Kirsten Axelsen, MS,Onur Baser, PhD, MS,Dale A. Rublee, PhD,Kimberly A. McGuigan, PhD, MBA 
